The use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21.

ABSTRACT: In recent years, there has been an increasing tendency to create drugs based on certain commensal bacteria of the human microbiota and their ingredients, primarily focusing on live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, termed pharmacobiotics, necessitates an understanding of their mechanisms of action and the identification of pharmacologically active ingredients that determine their target properties. Typically, these are complexes of biologically active substances synthesized by specific strains, promoted as LBPs or postbiotics (including vesicles): proteins, enzymes, low molecular weight metabolites, small RNAs, etc. This study employs omics technologies, including genomics, proteomics, and metabolomics, to explore the potential of Limosilactobacillus fe

SUBMITTER: Odorskaya MV 

PROVIDER: S-EPMC11197932 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature